The glycosphingolipid inhibitor eliglustat inhibits autophagy in osteoclasts to increase bone mass and reduce myeloma bone disease
H. Leng, H. Zhang, L. Li, S. Zhang, Y. Wang, A. Ersek, E. Morris, E. Sezgin, Y.-H. Lee, Y. Li, J. Mi, Q. Zhong, C. Edwards, A. K. Simon, N. J. Horwood
Eliglustat inhibits autophagy in osteoclasts, reducing MM bone disease and suggesting its use as a treatment for bone loss disorders.
bioRxiv · Feb 5, 2021 · PreprintCell Biology